Sign In
Buy AMRX
$18.09
+0.170 (+0.95%)
At Close: Jul 27, 2026
Amneal Pharma to buy Kashiv BioSciences in $1.1 billion deal
06:46am, Wednesday, 22'nd Apr 2026
Amneal Pharmaceuticals has agreed to acquire biopharma firm Kashiv BioSciences in a cash-and-stock deal worth up to $1.1 billion that will expand the drugmaker's biosimilars business.
Kashiv BioSciences Agrees to Be Acquired by Amneal Pharmaceuticals to Create a Fully Integrated Global Biosimilar Leader
06:17am, Wednesday, 22'nd Apr 2026
PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv”), today announced that it has entered into a definitive agreement to be acquired by Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity – – Transaction Accelerates Growth Profile and Diversification – – Preliminary Q1 Results Reflect Cont
Amneal: A Robust Drug Portfolio Worth Watching, Driving Further Upside Potential
04:59pm, Tuesday, 21'st Apr 2026
Amneal Pharmaceuticals, Inc. remains a Buy, driven by robust top-line growth, a diversified drug pipeline, and macro demand in key clinical areas. AMRX's FY2025 revenue grew 8% to $3.02B, with positiv
A Look at Amneal Pharmaceuticals Inc (AMRX) After 4.7% Decline -- GF Value $6.98 vs Price $13.26
05:56pm, Monday, 20'th Apr 2026
On April 20, 2026, Amneal Pharmaceuticals Inc (AMRX) shares fell 4.7%, bringing the current price to $13.26. The stock has traded within a 52-week range of $7.0
Phase 4 ELEVATE-PD interim data (n=111) demonstrated clinically meaningful, consistent benefits of CREXONT across all prior treatment groups Demonstrated substantial increases in daily “Good On” t
Amneal shares rise after UBS initiates at Buy, cites “best-in-group” growth in specialty pharma
11:39am, Friday, 17'th Apr 2026
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) shares rose 5.7% on Friday after UBS initiated coverage with a Buy rating and a $19 price target, citing what it sees as an attractive entry point following a
Amneal shares rise after UBS initiates at Buy, cites “best-in-group” growth in specialty pharma
07:36am, Friday, 17'th Apr 2026
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) shares rose 5.7% on Friday after UBS initiated coverage with a Buy rating and a $19 price target, citing what it...
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
08:00am, Tuesday, 14'th Apr 2026
BRIDGEWATER, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. launch of albuterol sulfate inhalation ae
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Sees Significant Decrease in Short Interest
01:29am, Tuesday, 14'th Apr 2026
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) saw a significant drop in short interest in March. As of March 31st, there was short interest totaling 7,193,959 shares, a drop of 33.6% f
AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook
12:00pm, Friday, 10'th Apr 2026
Amneal Pharmaceuticals heads into 2026 with diversified growth drivers, rising margins and a faster launch cadence supporting steady revenue expansion.
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside
11:55am, Friday, 10'th Apr 2026
Amneal Pharmaceuticals trades below peers on sales multiple despite strong gains, with a $14 target hinging on execution, mix shift, and margin strength.
Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing
11:51am, Friday, 10'th Apr 2026
Amneal Pharmaceuticals taps GLP-1 growth via a Pfizer-linked manufacturing deal, gaining exposure without clinical risks while scaling injectables and peptides.
Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term
10:46am, Friday, 10'th Apr 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
08:00am, Thursday, 09'th Apr 2026
BRIDGEWATER, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the launch of bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL
